Pancreatic islet transplantation is a promising treatment option for patients severely affected with type 1 diabetes. This report from CITR presents pre-and posttransplant human leukocyte antigen (HLA) class I sensitization rates in islet-alone transplantation. Data came from 303 recipients transplanted with islet-alone between January 1999 and December 2008. HLA class I sensitization was determined by the presence of anti-HLA class I antibodies. Panel-reactive antibodies (PRA) from prior to islet infusion and at 6 months, and yearly posttransplant was correlated to measures of islet graft failure. The cumulative number of mismatched HLA alleles increased with each additional islet infusion from a median of 3 for one infusion to 9 for three infusions. Pretransplant PRA was not predictive of islet graft failure. However, development of PRA >20% posttransplant was associated with 3.6-fold (p < 0.001) increased hazard ratio for graft failure. Patients with complete graft loss who had discontinued immunosuppression had significantly higher rate of PRA ≥ 20% compared to those with functioning grafts who remained on immunosuppression. Exposure to repeat HLA class I mismatch at second or third islet infusions resulted in less frequent development of de novo HLA class I antibodies when compared to increased class I mismatch. The development of HLA class I antibodies while on immunosuppression is associated with subsequent islet graft failure. The risk of sensitization may be reduced by minimizing the number of islet donors used per recipient, and in the absence of donor-specific anti-HLA antibodies, repeating HLA class I mismatches with subsequent islet infusions.
INTRODUCTION
antibodies against islet donor human leukocyte antigen (HLA) class I and II molecules. HLA sensitization can be explained by the absence of HLA matching at the Pancreatic islet transplantation is an emerging β-cell replacement approach to achieve insulin independence time of selection of donor pancreas and the use of multiple islet infusions to achieve a sufficient engrafted islet or improve glycemic control for patients with "brittle" type 1 diabetes (T1D). While insulin-independent rates mass to support insulin independence, practices that may expose an islet recipient to a number of mismatched have been ϳ60% at 1 year, islet graft function decreases over time with insulin independence rates declining to HLA alleles. The effect of HLA sensitization on islet graft func-ϳ13% at 5 years (1, 8, 10, 22, 26) . Many factors could contribute to either early or late loss of islet graft func-tion is not sufficiently clear (6) . The presence of anti-HLA antibodies pretransplant has been associated with tion, including posttransplant inflammation (13), potential toxicity of immunosuppressive drugs (24), recurrence of worse islet graft functional outcomes in some (4, 16) , but not all (7) , studies; however, the negative report did not autoimmunity (25, 28) , β-cell exhaustion (19, 27) , and alloimmune rejection. Several reports (4-7,9,15,16,18, determine donor specificity of the detected alloantibodies. The development of de novo anti-HLA antibodies 20,21) have shown the development of alloimmune responses in islet transplant recipients with detection of posttransplant has also been associated with islet graft failure (15, 18, 20) , although some islet transplant recipi- (11) . PRA provides the percent of cells that were either killed by patient's serum or the percent of cells that ents who develop positive panel-reactive antibodies (PRA) may continue to have well-functioning islet grafts showed binding of immunoglobulins to HLA proteins. We analyzed positive PRAs in this study as either (2, 7) . Regardless of the mechanism of islet graft deterioration, patients who discontinue immunosuppressive 1-19% or ≥ 20%. drugs following complete or partial islet graft loss seem Statistical Analysis to be at high risk for HLA sensitization (5, 7, 9, 21) .
The Collaborative Islet Transplant Registry (CITR) Descriptive statistics are presented as numbers for contains data on islet transplantation contributed from qualitative variables and mean ± SD or median with 28 North American medical institutions, three European, range for quantitative variables. Boxplots are used to and two Australian centers between January 1999 and summarize data. The "star" in the boxplot represents the December 2008. As of April 2009, the registry conmean value while the lower, middle, and upper lines of tained data from 412 islet transplant recipients of 828 the box represent the 25th, 50th, and 75th percentile, infusions derived from 905 donor organs (26) . This respectively. The square roots of pretransplant and 2report describes the analysis of HLA class I sensitization year posttransplant PRA were plotted. McNemar's test among 303 islet-alone transplant recipients. The role of was used to determine if islet transplantation was associmultiple islet infusions, the number of HLA mismatches, ated with developing a posttransplant PRA ≥ 20%. Uniand immunosuppression withdrawal on the development variate analysis was performed using chi-square test to of HLA class I sensitization were analyzed, as well as compare number of PRA ≥ 20% patients with pretransthe effect of HLA sensitization on islet graft failure.
plant PRA, number of islet infusions, and with reexpo-Currently the data on HLA class II PRA are incomplete.
sure to HLA class I mismatches. Proportional hazards Efforts are being made to complete data collection on analysis of time to graft failure was performed with sensitization to HLA class II and a comprehensive analfixed and time-varying covariates. A value of p < 0.05 ysis will be the focus of future reports.
was considered statistically significant. All analyses were performed in SAS 9.2 for Windows (SAS Institute MATERIALS AND METHODS Inc., Cary, NC). Islet transplant centers contributing to the CITR RESULTS obtained local IRB approval and written informed consent from all patients whose data were entered. The data
The number of patients analyzed was 303 from 27 are rigorously monitored to comply with Code of Fedcenters; 81 patients received one, 144 patients received eral Regulations (CFR) requirements. This study reports two, and 78 patients received three or more infusions. an analysis of data collected from 303 recipients trans-
The mean age of the recipients was 44 ± 9.7 years and planted with islets alone between January 1999 and included 108 males and 195 females ( Table 1) . Fourteen December 2008. Patients receiving allogeneic islet-alone out of 303 patients had a pretransplant PRA ≥ 20% and transplants generally are required to have had type 1 dia-37/303 patients had low levels (1-19%) of PRA. The betes mellitus for more than 5 years, be between 18-65 years of age, and have extreme difficulties with glycemic control indicated by either hypoglycemia unaware- immunosorbent assay (ELISA) using antigen coated 1-19% 37 trays, FLOW PRA, which is based on antigen-coated >20% 14 fluorescent beads, and/or Luminex solid phase assays registry does not have alloantibody specificity data, and PRA during pretransplant period (Q3) was determined to have resolved with a decrease in PRA to 0%. After so cannot determine whether unacceptable antigens were avoided and/or if prospective cross-matches were nega-two islet infusions the increase in number of patients with ≥20% PRA (13/83) was more when compared to tive before proceeding with the islet transplantation in these 51 PRA positive patients.
one infusion (2/42). Surprisingly among 27 patients with three infusions, there was no evidence of increase in PRA. The median number of class I (A and B) mismatches at first islet infusion was 3 with a range of 0 to 8. A
The cumulative incidence of class I PRA ≥20% among 250 islet transplant patients under immunosup-mismatch of 5 to 8 class I antigens reflects infusion of combined islet preparations from two donor pancreata.
pression is shown in Figure 3 . At 1 year post-first infusion 3% of patients developed a class I PRA ≥20% and The median number of mismatches increased to 6 (range 2-12) for the second infusion and 9.5 (range 6-15) for the incidence increased to 9% at 2 years, 13% at 3 years, 26% at 5 years, and 33% at 6 years. As shown in Figure the third infusion ( Table 2) .
Among patients with complete graft loss median PRA was 5% at 6 months, 0% at 1 year, 4.5% at 2 years, and The prevalence of a class I PRA ≥ 20% before and after one (A) or two (B) or three (C) islet infusions is 25% at 3 years posttransplant. In an analysis of PRA as a predictor of time to initial graft failure, elevated base-shown in Figure 1 . The follow-up period was 6 months and yearly after 1 year for up to 3 years. At first infusion line PRA was not a risk factor as failure rates were 100/ 252 (39.7%), 20/37(54.1%), and 3/14(21.4%) for those 289 patients were <20% for class I PRA. During the follow-up period after a single islet infusion, 4/102 at 6 with 0% PRA, 1-19, and ≥20, respectively. Among those with % PRA 0-19 at baseline, recent elevation of months, 4/70 at 1 year, 4/42 at 2 years, and 4/25 at 3 years had a PRA ≥20%. At the time of a second islet PRA ≥20% during follow-up was a risk factor for graft failure (HR = 3.6, p < 0.0014). infusion 4/197 patients were PRA ≥20%, and subsequently 2/123 were ≥20% at 6 months, 6/109 at 1 year,
We analyzed development of posttransplant PRA ≥20% by baseline and treatment characteristics ( Table  9 /81 at 2 years, and 8/58 at 3 years. Similarly 1/69 patients who received a third islet infusion was ≥20%
3). Among 217 patients with 0% PRA before islet transplant, 13% (28/217) developed ≥20% PRA, whereas for class I PRA at the time of infusion, and then 1/40 were ≥20% at 6 months, 0/38 at 1 year, 0/28 at 2 years, 38% of patients with 1-19% PRA at baseline showed development of ≥20% PRA. This data showed that pres-and 4/23 at 3 years. Figure 2 shows the development of class I PRA ence low levels PRA at first infusion will significantly increase (p < 0.001) the possibility of development class (≥20%) at 2 years post-final infusion when compared to the pretransplant status after one, two, or three islet I PRA to ≥20%. However multiple islet infusions did not increase the possibility of development of class I infusions in 161 patients under immunosuppression. Of 152 patients with pretransplant class I PRA <20% (Q1 PRA of ≥20% significantly when compared to single infusion (15% vs. 20%; p < 0.26). HLA class I sensitiza-and Q3) and assayed at 2 years post-final islet infusion, 15 (9.9%) developed a PRA ≥20%. The increase was tion (≥20% PRA) among patients reexposed to repeat HLA donor mismatches (8%; n = 39) was less than significant (p < 0.001) and the one case showing ≥20% those patients who were not reexposed (20%; n = 35). approaches that can achieve insulin independence after single islet transplantation will minimize patient's expo-However, this difference did not reach statistical significance (p < 0.12) as shown in Table 3 .
sure to HLA mismatches which in turn may decrease the risk for allosensitization. Another important issue for the transplantation of DISCUSSION islets mismatched for HLA is the effect of pretransplant sensitization on subsequent islet graft function and sur-This report of CITR data represents the largest analysis to date of HLA class I sensitization in islet transplant vival. The inadvertent transplantation of islets to recipients presensitized against donor-specific HLA can result recipients. The results show that i) multiple islet infusions increased the number of HLA mismatches to in rapid islet graft loss (16), and the presence of a pretransplant class I PRA >15% was associated with islet which transplant recipients were exposed; ii) multiple islet infusions did not further increase the risk of sensiti-graft failure that was largely explained by the presence of islet donor-specific antibodies (4). In the present zation over a single islet infusion; iii) the proportion of patients developing anti-HLA class I antibodies increased report, we did not find a significant relationship between a positive PRA pretransplant and subsequent islet graft over time even in the presence of immunosuppression; and iv) the development of a posttransplant PRA ≥20% failure; however, donor specificity data were not available. Most centers now perform prospective cross-was associated with subsequent islet graft failure. The limited pool of donor organs precludes efficient islet matches, and in the cases of positive PRA pretransplant, avoid unacceptable antigens by excluding donors with transplant allocation according to HLA matching. Hence, it is expected that multiple infusions will expose the same specificities as anti-HLA antibodies regardless of the cross-match (21) . recipients to increased numbers of HLA mismatches. Our results confirm this expected outcome as the major-De novo HLA sensitization may also be one of the factors that are associated with loss of islet graft func-ity of islet recipients who received two islet infusions were exposed to at least six HLA class 1 mismatches.
tion. The adverse effect of HLA sensitization in recipients of kidney (12,14), heart (3), and lung (23) transplants Data from the Edmonton group (4, 5) showed that the median number of class I mismatches was 3 with a has been reported earlier. Among pancreas transplant recipients (simultaneous pancreas kidney), 21% devel-range of 0-7, and for both class I and II the number of mismatches in their patient population ranged from oped anti-HLA antibodies (6) , and the presence of anti-HLA antibodies correlated with poor pancreas graft 1-19 with a median of 8.5; however, there was no relationship between the number of mismatches and the survival. Islet grafts may be more "sensitive" to humoral immunity when compared to solid organ grafts and may development of HLA antibodies. Development of demonstrated a temporal relationship with the development of islet donor specific anti-HLA antibodies and subsequent islet graft functional deterioration and failure (15, 20) , although there have also been cases reported where the development of donor specific anti-HLA antibodies was not related to any deterioration in islet graft function (2) or long-term survival (7) . Nonetheless, based on results from a larger pool of patients, Campbell et al. (5) have reported that 26 out of a total of 98 (27%) islet transplant patients developed de novo donor specific anti-HLA antibodies while on maintenance immunosuppression that was associated with significantly worse islet graft function when compared to the patients without sensitization. The data reported here extend these findings by demonstrating a significantly increased risk for islet graft failure following the development of a PRA ≥20% posttransplant.
Our data also confirm earlier reports (5, 7, 9, 21) of increased HLA sensitization among patients with failed islet grafts who discontinued their immunosuppression. Development of HLA sensitization among these patients remains a concern because of the potentially prolonged waiting time for subsequent organ transplants (e.g., pancreas or kidney), if needed. A final consideration is that the type of immunosuppression may have a major effect on anti-HLA antibody production. While the Edmonton group showed that 27% of patients treated with glucocorticoid-free immunosuppression develop de novo anti-HLA antibodies (5), the Geneva group (9) demonstrated that 0/27 patients receiving low-dose glucocorticoids as part of their immunosuppression for previous or simultaneous kidney transplants developed de novo anti-HLA antibodies, whereas 2/8 patients receiving Edmonton immunosuppression and 2/3 patients during withdrawal of immunosuppression became sensitized. These results suggest that glucocorticoid-free immunosuppression may not sufficiently control the development of alloimmune response to transplanted islets.
In summary, the present report demonstrates that the development of anti-HLA class I antibodies posttransplant represents a significant risk for subsequent islet graft failure. nonsensitized patients. Subsequent reports have also Patients with pretransplant PRA <20% and at least one known posttransplant PRA measurement. *Restricted to recipients of two islet infusions.
